Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Today's picks- 22 October 2014

Nifty, Bank Nifty, Cipla & Tata Motors

Groundnut exports jump 38% in first half of FY 15

India exported over 220,000 tonnes of groundnut between April and September 2014

BSE shareholders approve BSE-USE merger

A news release from the BSE said that the BSE and USE will now be filing necessary petitions before the Bombay High Court

Sept steel output drops in major nations; India logs rise

In India steel production grew by 2.5% to 6.8 MT during the month

BSE shareholders approve merger with United Stock Exchange

BSE and USE will now be filing necessary petitions before the Bombay High Court seeking its sanction to the proposed scheme

Back to Top